首页>
外国专利>
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
展开▼
机译:CXCL11和SMICA作为抗CTLA4免疫疗法疗效的预测生物标志物
展开▼
页面导航
摘要
著录项
相似文献
摘要
Provided herein are methods for selecting a cancer patient for anti-CTLA-4 immunotherapy, or predicting whether a cancer patient will respond to anti-CTLA4 immunotherapy, based on measured levels of CXCL1 1 and/or sMICA. Such methods are useful for determining whether an anti-CTLA-4 immunotherapy is likely to improve overall survival of a cancer patient. Also provided herein are methods of treating a cancer patient with an anti-CTLA-4 immunotherapy, wherein the patient is first tested for levels of CXCL1 1 and/or sMICA. Also provided are methods for treating a cancer patient with a CXCL1 1 antagonist or sMICA ant agonist alone, or in combination with each other and/or with additional anti-cancer agents, such as a CTLA-4 antagonist.
展开▼